← Search & browse all drugs
NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Selective serotonin (5HT1) agonists
frovatriptan
N02CC07
Forms & Strengths
- Tablets: 2.5 mg
- Scored tablets for oral administration
Adult Dosing
- Initial dose: 2.5 mg
- May repeat after 2 hours if symptoms return
- Maximum dose per 24 hours: 7.5 mg
- Not recommended for prophylactic use
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years
- Contraindicated in pediatric patients due to limited data
Indications
- Acute treatment of migraine with or without aura
- Relief of migraine headache pain
Mechanism of Action
- Selective agonist of 5-HT1B/1D receptors
- Binds to serotonin receptors on blood vessels and nerves
- Produces vasoconstriction and inhibits pro-inflammatory neuropeptide release
Contraindications
- Hypersensitivity to frovatriptan or any component
- Ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular disease
- Cerebrovascular disease, including stroke and TIA
- Peripheral vascular disease
- Uncontrolled hypertension
- Basilar or hemiplegic migraine
Adverse Reactions
- Most common: dizziness, paresthesia, headache, fatigue, nausea, and dry mouth
- Serious: myocardial infarction, angina, and arrhythmias
- Rare: hypersensitivity reactions, including anaphylaxis and angioedema
Drug Interactions
- MAOIs: contraindicated within 2 weeks of MAOI use
- SSRIs, SNRIs, and TCAs: increased risk of serotonin syndrome
- Ergotamines and other triptans: increased risk of additive vasospastic effects
Curated Content: Needs Vetting Before Put to Clinical Use